Blar i Sentraladministrasjonen på emneord "Non-Hodgkin lymphoma"
Viser treff 1-1 av 1
-
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
(Acta Oncologica;Volume 60, 2021 - Issue 11, Peer reviewed; Journal article, 2021-08-23)Background: The aim of this study was to investigate dosimetry data and clinical variables to predict hematological toxicity in non-Hodgkin lymphoma (NHL) patients treated with [177Lutetium]Lu-liloto-mab satetraxetan. Material ...